A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

A Phase 2, Single-masked, Randomized, Crossover Study Of The 24-hour Intraocular Pressure Lowering And Systemic Exposure of Pf-04217329 Alone And In Combination With Latanoprost

This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.

Inclusion Criteria:

• Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes
• Intraocular Pressure (IOP) of at least 22 mmHg and not more than 30 mmHg in either eye at 8 AM after discontinuing previous glaucoma treatment
• Visual acuity correctable to 20/100 or better in each eye.

Exclusion Criteria:

• Closed/barely open anterior chamber angle or a history of acute angle closure in either eye.
• Diagnosis of a clinically significant or progressive retinal disease (eg, diabetic retinopathy, macular degeneration) in either eye.
• Advanced glaucoma or a history of severe central visual field loss in either eye.
• History of ocular surgery or trauma in either eye within 6 months of the screening visit.
• History of ocular infection, ocular inflammation, or laser surgery in either eye within 3 months of the screening visit.